Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Application of J‑Plasma in the excision of diaphragmatic lesions as part of complete cytoreduction in patients with advanced ovarian cancer

Application of J‑Plasma in the excision of diaphragmatic lesions as part of complete... For the resection of diaphragmatic disease in patients with advanced ovarian cancer (OC), a plethora of ablative methods have been utilized. The present study aimed to present preliminary data on the use of J‑Plasma in OC with diaphragmatic involvement via a retrospective review of patients who had diaphragmatic stripping with of J‑Plasma<sup><sub>®</sub></sup> from January 2016 to September 2020. A total of 12 patients (median age, 65 years) were analyzed. Median operative time was 240 min while median estimated blood loss was 400 ml. Median operative time for diaphragmatic resection was 25 min. During a median follow‑up of 12 months, two recurrences were noted while none of the patients died of the disease. Median disease free survival was 12 months. Overall, the preliminary outcomes of the present study indicated that J‑Plasma could be safely used in diaphragmatic resection and it was associated with low rates of short‑term morbidity. However, further studies are warranted to reach to safe conclusions. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Molecular and Clinical Oncology Spandidos Publications

Application of J‑Plasma in the excision of diaphragmatic lesions as part of complete cytoreduction in patients with advanced ovarian cancer

Download PDF
6 pages

Loading next page...
 
/lp/spandidos-publications/application-of-j-plasma-in-the-excision-of-diaphragmatic-lesions-as-sJPDIRHLoa

References (24)

Publisher
Spandidos Publications
Copyright
Copyright © 2022 Spandidos Publications
ISSN
2049-9450
DOI
10.3892/mco.2022.2546

Abstract

For the resection of diaphragmatic disease in patients with advanced ovarian cancer (OC), a plethora of ablative methods have been utilized. The present study aimed to present preliminary data on the use of J‑Plasma in OC with diaphragmatic involvement via a retrospective review of patients who had diaphragmatic stripping with of J‑Plasma<sup><sub>®</sub></sup> from January 2016 to September 2020. A total of 12 patients (median age, 65 years) were analyzed. Median operative time was 240 min while median estimated blood loss was 400 ml. Median operative time for diaphragmatic resection was 25 min. During a median follow‑up of 12 months, two recurrences were noted while none of the patients died of the disease. Median disease free survival was 12 months. Overall, the preliminary outcomes of the present study indicated that J‑Plasma could be safely used in diaphragmatic resection and it was associated with low rates of short‑term morbidity. However, further studies are warranted to reach to safe conclusions.

Journal

Molecular and Clinical Oncology – Spandidos Publications

Published: Jul 28, 2022

There are no references for this article.